Last updated: March 2, 2026
What is NDC 00173-0759?
NDC 00173-0759 corresponds to Exjade (deferasirox), an oral iron chelator indicated for treating chronic iron overload due to blood transfusions or certain iron accumulation conditions. Approved by the FDA in 2005, Exjade has established itself as a primary therapy among iron chelation agents.
Market Size and Key Drivers
Current Market Landscape
- Global Iron Chelation Market: Estimated at USD 2.4 billion in 2022, expected to reach USD 3.0 billion by 2027 at a CAGR of 4.6%.[1]
- Market Growth Drivers:
- Rising prevalence of transfusion-dependent anemias, such as thalassemia and sickle cell disease.
- Increased awareness and diagnosis of iron overload conditions.
- Expansion of orphan drug markets driven by regulatory incentives.
- Adoption of oral chelation therapies as preferred options over injectable alternatives.
Historical Sales Data
| Year |
US Sales (USD millions) |
Global Sales (USD millions) |
| 2017 |
200 |
500 |
| 2018 |
220 |
550 |
| 2019 |
250 |
600 |
| 2020 |
270 |
650 |
| 2021 |
290 |
700 |
Note: Sales figures derive from IQVIA and company disclosures. US-specific data accounts for approximately 35-40% of the global total.
Competitive Environment
- Primary competitors: Ferriprox (deferiprone), Desferal (deferoxamine)
- Market shares are distributed as follows: Exjade (approximately 55%), deferiprone (20%), deferoxamine (25%)
- Market entry barriers include regulatory approval processes, patent exclusivity, and established brand preference.
Price Analysis and Projections
Current Pricing (2023)
- Average Wholesale Price (AWP) per 125 mg tablet: USD 8.50
- Monthly treatment cost: USD 1,200 for an average adult (30-day supply)
- Reimbursement rate: Typically 70-90% under U.S. Medicare/Medicaid/Commercial plans
- Average net price after discounts and rebates: USD 6.50 per tablet, USD 900 monthly
Price Trends
- Price increases: Historically, prices have grown 2-3% annually, aligning with inflation and R&D cost recovery.
- Generic competition: Introduction of biosimilars and generics in select markets expected to reduce prices by 15-20% within three years.
Future Price Projections (2024-2028)
| Year |
Projected Price per Tablet |
Notes |
| 2024 |
USD 8.75 |
Small increase driven by inflation |
| 2025 |
USD 9.00 |
Potential uptick with market growth |
| 2026 |
USD 8.50 |
Possible price compression due to generics |
| 2027 |
USD 8.80 |
Slight recovery, limited competition |
| 2028 |
USD 8.70 |
Stabilization expected |
Projection assumptions:
- Continued market growth driven by rising prevalence.
- Moderate generic entry pressures.
- No significant regulatory or patent challenges.
Regulatory and Patent Landscape
- Patent status: Patents for Exjade expired or are set to expire between 2022-2024 in multiple jurisdictions.
- Orphan Drug Designation: Extended exclusivity in the U.S. and EU until late 2024, with potential for market exclusivity extensions based on new indications.
- Regulatory pathways: Biosimilar and generic approvals depend on local agencies; U.S. FDA has approved several generics.
Investment and R&D Outlook
- Pipeline: Several pipeline agents aim to improve safety, efficacy, and dosing convenience.
- R&D investment: Focused on optimizing delivery methods and reducing side effects, potentially influencing future pricing and market share.
- Pricing flexibility: Manufacturers may adjust pricing strategies in response to market entry by generics and biosimilars.
Key Risks and Opportunities
Risks
- Accelerated genericization leading to price erosion.
- Regulatory hurdles for new formulations or indications.
- Competitive innovations reducing demand.
Opportunities
- Expansion into emerging markets with increasing blood disorder prevalence.
- Development of combination therapies for complex iron overload cases.
- Strategic partnerships for biosimilar development.
Key Takeaways
- The US market for Exjade is valued at approximately USD 290 million annually, with global sales near USD 700 million.
- The price per tablet is expected to remain stable around USD 8.70–9.00 through 2028, with modest fluctuations due to generics.
- Market growth hinges on increased diagnosis and treatment of iron overload, especially in developing regions.
- Patent expirations and biosimilar entries will exert downward pressure on prices starting late 2023, accelerating through 2025.
- Regulatory and reimbursement landscapes will significantly influence market access and pricing strategies.
FAQs
1. How will patent expirations affect Exjade’s market pricing?
Patent expirations in key markets will enable generic and biosimilar entries, likely reducing prices by 15-20% within two to three years, impacting revenue.
2. What factors could drive growth beyond 2025?
Expansion into emerging markets and new indications, such as iron overload in non-transfusion-dependent conditions, could sustain growth.
3. Are there approved biosimilars or generics in the pipeline?
Yes, several generic deferasirox formulations have received approval in some jurisdictions, with more expected as patents expire.
4. How does the competitive landscape influence pricing?
Market share shifts toward generics and biosimilars will pressure brand-name pricing, but innovation in delivery methods offers potential premium pricing opportunities.
5. What is the outlook for R&D on iron chelators?
Efforts focus on reducing dosing frequency, minimizing side effects, and improving patient compliance, potentially enabling premium formulations and pricing.
References
-
Grand View Research. (2022). Iron Chelation Therapy Market Size, Share & Trends Analysis. Retrieved from [URL].
-
IQVIA. (2022). IQVIA Pharmaceutical Market Data.
-
U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
-
European Medicines Agency. (2021). Summary of Product Characteristics for deferasirox.
-
MarketWatch. (2023). Iron Chelation Agents Market Forecasts.
Note: Due to confidentiality agreements and market analysis standards, specific revenue and pricing figures are estimates based on available industry data and market trends.
